208 related articles for article (PubMed ID: 30910278)
1. Management of dyslipidaemias in the elderly population-A narrative review.
Anagnostis P; Vaitsi K; Veneti S; Georgiou T; Paschou SA; Lambrinoudaki I; Goulis DG
Maturitas; 2019 Jun; 124():93-99. PubMed ID: 30910278
[TBL] [Abstract][Full Text] [Related]
2. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
Reklou A; Katsiki N; Karagiannis A; Athyros V
Curr Vasc Pharmacol; 2020; 18(1):38-42. PubMed ID: 30663570
[TBL] [Abstract][Full Text] [Related]
3. Nonstatin therapies for management of dyslipidemia: a review.
Sando KR; Knight M
Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease.
Katsiki N; Mikhailidis DP; Banach M
Expert Opin Pharmacother; 2019 Nov; 20(16):2007-2017. PubMed ID: 31344332
[No Abstract] [Full Text] [Related]
5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
6. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
O'Keefe JH; DiNicolantonio JJ; Lavie CJ
Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
[TBL] [Abstract][Full Text] [Related]
7. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
Ito MK
Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
[TBL] [Abstract][Full Text] [Related]
8. Personalized medicine in lipid-modifying therapy.
Tomlinson B; Lin CH; Chan P; Lam CW
Per Med; 2021 Mar; 18(2):185-203. PubMed ID: 33565320
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
10. New concepts in the management of dyslipidaemiaa.
Gencer B; Rodondi N; Mach F
Swiss Med Wkly; 2016; 146():w14378. PubMed ID: 27878791
[TBL] [Abstract][Full Text] [Related]
11. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
13. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
14. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
15. Lipid management in patients with chronic kidney disease.
Ferro CJ; Mark PB; Kanbay M; Sarafidis P; Heine GH; Rossignol P; Massy ZA; Mallamaci F; Valdivielso JM; Malyszko J; Verhaar MC; Ekart R; Vanholder R; London G; Ortiz A; Zoccali C
Nat Rev Nephrol; 2018 Dec; 14(12):727-749. PubMed ID: 30361677
[TBL] [Abstract][Full Text] [Related]
16. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
Gebauer K; Reinecke H
Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
[TBL] [Abstract][Full Text] [Related]
19. Managing dyslipidaemia in type 2 diabetes mellitus.
Szalat A; Durst R; Leitersdorf E
Best Pract Res Clin Endocrinol Metab; 2016 Jun; 30(3):431-44. PubMed ID: 27432076
[TBL] [Abstract][Full Text] [Related]
20. Consensus statement on the management of dyslipidaemias in adults.
; ; ; Béliard S; Bonnet F; Bouhanick B; Bruckert E; Cariou B; Charrière S; Durlach V; Moulin P; Valéro R; Vergès B
Diabetes Metab; 2016 Dec; 42(6):398-408. PubMed ID: 27659248
[No Abstract] [Full Text] [Related]
[Next] [New Search]